Related Experiment Videos
The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal
Matta Csaba1,2,3, Roland Takács1, Eun-Jung Jin2,3,4
1Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Introduction:
Transient receptor potential vanilloid 1 (TRPV1) has been pursued as a therapeutic target in osteoarthritis (OA) pain for over two decades. Both systemic antagonism and localized agonism advanced into clinical development, supported by mechanistic rationale and preclinical data.
Areas Covered:
We critically appraise TRPV1-targeted drug development in OA, examining the biological basis of the target, translational trajectories of antagonist and agonist programs, and clinical trial outcomes that define the current landscape. Literature was identified through a PubMed search for peer‑reviewed articles on TRPV1 and OA over the past 5 years, followed by manual selection of key references. We review why systemic TRPV1 antagonists were abandoned, and why intra-articular TRPV1 agonists, despite expedited regulatory designations, failed to meet primary endpoints in Phase III trials.
Expert Opinion:
TRPV1-targeted therapy in OA has completed a full translational cycle without yielding regulatory approval. The mechanistic rationale remains valid; what failed was clinical translation. Key contributors include over-reliance on preclinical models poorly capturing central sensitization, lack of stratification by peripheral versus central pain phenotypes, and use of composite pain endpoints in phenotypically mixed populations. The TRPV1 experience offers lessons for peripheral analgesic development in OA: patient phenotyping and enrichment must precede pivotal trials.
Insights
Transient receptor potential vanilloid 1 (TRPV1) targeted osteoarthritis (OA) pain therapies failed in clinical trials. Lessons learned emphasize patient phenotyping and enrichment for future peripheral analgesic development.
Area of Science:
- Pharmacology
- Pain Management
- Osteoarthritis Research
Background:
- Transient receptor potential vanilloid 1 (TRPV1) is a key target for osteoarthritis (OA) pain.
- Both systemic antagonists and localized agonists have been explored in clinical development.
Purpose of the Study:
- Critically appraise TRPV1-targeted drug development for OA pain.
- Examine the biological basis, translational trajectories, and clinical outcomes of TRPV1 programs.
- Identify reasons for clinical trial failures in OA pain management.
Main Methods:
- Literature search of PubMed for peer-reviewed articles on TRPV1 and OA (last 5 years).
- Manual selection of key references for critical appraisal.
- Review of systemic antagonist and intra-articular agonist programs.
Main Results:
- Systemic TRPV1 antagonists were abandoned during development.
- Intra-articular TRPV1 agonists failed to meet primary endpoints in Phase III trials despite expedited designations.
- TRPV1-targeted OA therapy has not achieved regulatory approval.
Conclusions:
- TRPV1-targeted OA therapy has completed a full translational cycle without success.
- Clinical translation failed due to over-reliance on preclinical models, inadequate patient stratification, and composite endpoints.
- Future peripheral analgesic development for OA requires robust patient phenotyping and enrichment strategies.
